ArticleBreast cancer research : BCR2026
TLScope: a deep learning framework for quantifying tertiary lymphoid structures from H&E images reveals prognostic heterogeneity across breast cancer subtypes.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Tertiary lymphoid structures (TLSs) are ectopic immune aggregates associated with antitumor immunity and favorable prognosis in various cancers. However, standardized approaches for TLS detection and quantification in breast cancer remain underdeveloped. We present TLScope, a deep learning-based framework that accurately identifies and quantifies TLSs in hematoxylin and eosin (H&E)-stained whole-slide images (WSIs) of breast cancer. TLScope combines cell-level classification, tumor and adipose region segmentation, and biologically informed TLS validation to enable scalable analysis of TLS density. Applied to over 1000 WSIs from internal and TCGA cohorts, TLScope revealed significant associations between TLS density and clinicopathological features. TLSs were more frequently observed in tumors with higher histological grades and elevated Ki-67 expression. Moreover, patients with more TLSs exhibited improved overall survival. Although TLSs were most abundant in HER2-enriched and basal-like subtypes, their prognostic value was most pronounced in Luminal B tumors, suggesting a context-dependent role of TLSs in breast cancer. This work provides a standardized and interpretable tool for TLS assessment in breast cancer, facilitating deeper insights into tumor-immune interactions and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.